Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo
NovoThirteen
Type 2 diabetes
1 trial -
cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide
NovoThirteen
Overweight and obesity
1 trial -
cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo
NovoThirteen
Overweight and obesity
1 trial -
camizestrant, Arimidexยฎ 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G
AstraZeneca AB
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1 trial -
canakinumab
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
2 trials -
centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).
DiaMedica Therapeutics
Acute Ischemic Stroke
1 trial -
cleminorexton
Centessa Pharmaceuticals plc
Narcolepsy Type 1
1 trial -
deucravacitinib, Placebo to match BMS 986165 tablet
Bristol-Myers Squibb Australia Pty Ltd
Moderate-to-Severe Plaque Psoriasis
1 trial -
deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use
Bristol-Myers Squibb Australia Pty Ltd
Moderate to Severe Plaque Psoriasis
1 trial -
deucravacitinib, Placebo to match deucravacitinib tablet
Bristol-Myers Squibb Australia Pty Ltd
Active Psoriatic Arthritis
1 trial -
deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib
Bristol-Myers Squibb Australia Pty Ltd
Juvenile Psoriatic Arthritis (JPsA)
1 trial -
eN-Lacยฎ
Biotech Pharmaceutical Co.,
Perennial Allergic Rhinitis
1 trial -
eRapa (encapsulated rapamycin)
Biodexa Pharmaceuticals Plc
Familial Adenomatous Polyposis (FAP)
1 trial -
elafibranor, Elafibranor Placebo
Ipsen
Primary Biliary Cholangitis (PBC)
1 trial -
elafibranor, Placebo
Ipsen
Primary Biliary Cholangitis
1 trial -
elafibranor, Placebo tablet
Ipsen
Primary Biliary Cholangitis
1 trial -
elritercept, Placebo to match ker-050 solution for injection
Takeda
myelodysplastic neoplasms/syndromes (MDS)
1 trial -
epinephrine inhalation aerosol
Amphastar France Pharmaceuticals
Asthma
2 trials -
evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)
Wuhan Createrna Science and Technology Co., Ltd
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
1 trial -
experimental anti-anxiety drug
Jazz Pharmaceuticals Ireland Limited
Anxiety Disorder
1 trial -
fluocinolone acetonide
ANI PHARMACEUTICALS INC
Diabetic Macular Edema
3 trials -
granules for suspension, N-Acetyl-L-Leucine
Intrabio Ireland Limited
Ataxia Telangiectasia
1 trial -
ianalumab
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
ianalumab s.c. q4w
Novartis Pharmaceuticals
Lupus Nephritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources